AUTHORS
Eirini Solia, MD, Foteini Theodorakakou, MD2, Nikolaos Kanellias, MD, PhD3, Ioannis Ntanasis-Stathopoulos, MD4, Panagiotis Malandrakis, MD, MSc, PhD5, Evangelos Eleutherakis-Papaiakovou6, Ilias Katsadouros, MD7, Panagiotis Boutsikos, MD8, Aikaterini Nikolopoulou, MD9, Magdalini Migkou10, Maria Gavriatopoulou, MD11, Evangelos Terpos, MD12, Meletios-Athanasios (Thanos) C. Dimopoulos, MD13, Efstathios Kastritis, MD14
AFFILIATIONS
1 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
2 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
3 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
4 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
5 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
6 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
7 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
8 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
9 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
10 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
11 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
12 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
13 Korea University, Seoul, Korea, Rep. of South, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
14 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
ABSTRACT
Introduction: Evaluation of the risk of progression to symptomatic disease is crucial for the appropriate follow-up and management of pts with smoldering multiple myeloma (SMM). To this end, clinical prognostic scores are the main tools in the everyday clinical practice and stratification in clinical trials. The International Myeloma Working Group (IMWG) 20/2/20 prognostic model is simple and easy to calculate (based on three simple variables, the free light chain ratio, M-protein concentration and percentage of bone marrow (BM) plasma cells) and has been widely used to stratify SMM patients (pts) into three prognostic subgroups, but provides a static image. The Pangea 2.0 models incorporate additional variables to provide a more individualized risk prediction and incorporate dynamic predictions. Given the importance of initial risk assessment we focused on the baseline risk assessment and evaluated the 20/2/20 and Pangea 2.0 models in an independent cohort of SMM pts at the time of the diagnosis.
Methods: We analyzed consecutive SMM pts diagnosed at the Department of Clinical Therapeutics, Athens, using the IMWG 2014 criteria. All pts had a BM biopsy at diagnosis and were assessed at baseline and at regular follow up using advanced imaging. Pts were classified according to both the IMWG 20/2/20 and Pangea 2.0 risk stratification models (with and without BM) using clinical and laboratory parameters available at diagnosis. Median follow up was 3 years.
Results: A total of 394 pts were included, (median age of 64.5 (IQR: 56.25-74); 53.8% were females; 69.9%, 25.13% and 4.31% were IgG, IgA and light chain only SMM, respectively. Median BM infiltration was 15% (IQR: 10-20) while the median M-protein concentration was 1.1 g/dL (IQR: 0.70–1.62). During a median follow-up of 3 years, 52 (13.2%) pts progressed to symptomatic multiple myeloma; the 1- 2- and 3- year cumulative progression was 2%, 8% and 10% for the whole cohort.
Per the 20/2/20 model, 62% of pts were low, 26% intermediate and 12% high risk. The 2-year cumulative progression rate was 1.6%, 6.4%, and 14.7%, for low, intermediate and high-risk pts, respectively. p<0.001) suggesting a 11-fold higher risk of progression for high vs low risk groups (HR: 11, 95%CI 5-25) and a ~6-fold higher for intermediate vs low-risk pts (HR 6, 95%CI 3-12; p<0.001), while the risk of progression for high vs intermediate risk groups was ~2 fold ((HR 2.3, 95%CI 1.2-4.4; p=0.011). The model demonstrated satisfactory discrimination with a concordance index (C-index) of 0.777 and a satisfactory explained variation (R2=0.113).
The Pangea 2.0 model with BM data, provided a more individualized prediction of the 2-year progression risk and 18% were classified as having ≤2% probability (ultra-low risk), 35% with >2-5% probability (low-risk), 26% with >5-10% probability (intermediate risk) and 18% with >10-40% probability (“intermediate-High” risk) and 11 (3%) had ≥40% probability of progression at 2 years. The respective cumulative 2-year progression rate for these groups was 0%, 3%, 4%, 21% and 21% respectively (p<0.001). According to the Pangea 2.0 model without BM data, 25% were had ≤2% probability (ultra-low) of progression at 2 years, 36% with >2-5% probability (low-risk), 21% with >5-10% probability (intermediate risk) and 18% with >10-40% probability (“intermediate-High” risk) and just 1 patient ≥40% probability. The respective cumulative 2-year progression rate for these groups was 0%, 4%, 12%, 24% and 21% (p<0.001) (the single patient with >40% has not progressed). Overall, the two Pangea models, even when treated as static, with only baseline data, provided satisfactory discrimination (C-index:0.765 for the model with BM data and C-index:0.798 without BM data) and satisfactory explained variation (R2 of 0.091 and 0.092, respectively)
Conclusions: Both the IMWG 20/2/20 and PANGEA 2.0 models successfully stratify pts with SMM according to their baseline risk, however, as static models they have mostly negative predictive value for progression, with low-risk pts having very low probability of imminent (within 2-years) progression. Both models can be used to re-assure pts with low-risk SMM about their low probability of disease progression and complications; such pts should not be treated. Nonetheless, static models are insufficient for satisfactory risk prediction in intermediate or high-risk pts, which should be followed thoroughly according to the current guidelines.
DISCLOSURES
Eirini Solia, MD: No relevant conflicts of interest to declare.